Metabolic

Retatrutide

Triple GIP, GLP-1 and glucagon receptor agonist, currently in phase 3 clinical trials.

Phase 3

Overview

Retatrutide represents the next generation of incretin peptides: besides GIP and GLP-1, it also activates the glucagon receptor, hypothesised to increase energy expenditure. Phase 2 results published in 2023 led to the TRIUMPH phase 3 programme.

Mechanism of action

Agonism at GIP, GLP-1 and glucagon receptors. The glucagon component is investigated for its effects on energy expenditure and liver fat.

Research areas

  • Obesity
  • Type 2 diabetes
  • Fatty liver disease (MASLD)

Selected references

  1. Jastreboff AM et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389:514–526. PubMed ↗

More profiles

Full library